Condition: Hepatocellular Carcinoma · Radioembolization · Sponsor: Assistance Publique - Hôpitaux de Paris
OPERANDI project aims to address unmet clinical needs in the current management of advanced-stage HCC treated with TARE by exploring new opportunities provided by imaging-based artificial intelligence (AI) and data augmentation, simultaneous PET-MRI imaging, and novel approaches to increase patient selection and TARE efficacy (genomic profiling, radiopotentiators, and new radionuclides). The research aim to identify predictive and early markers indicative of TARE effectiveness based on a large prospective cohort of HCC patients. This cohort will be used to uncover relevant predictive signatures within the morphological, functional, and molecular imaging data using novel imaging-based AI approaches with a new patient imaging pathway including simultaneous 18F-Choline PET-MRI. Considering this global objective, the objective of this clinical research protocol is to provide clinical, molecular and imaging data in a prospective standardized study, notably by performing systematic pretherapeutic PET-MRI, in patients with HCC treated with TARE.
This description comes directly from the study's public registry record.
Valérie VILGRAIN · 00-33-1-40-87-53-58 · valerie.vilgrain@aphp.fr
Françoise KRAEBER - BODERE · 00-33-2-40-08-41-45 · francoise.bodere@chu-nantes.fr
Always discuss trial participation with your own doctor first.
| Service de Médecine Nucléaire, Hôpital Beaujon | Clichy, France | Recruiting |
| Beaujon hospital | Clichy, France | Recruiting |
| CHU Nantes | Nantes, France | Active Not Recruiting |
| Service de Médecine Nucléaire, CHU de Nantes | Nantes, France | Recruiting |
| Service de medecine nucleaire, Hôpital Bichat | Paris, France | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06334965